Biotech | September 21, 2021
HUTCHMED initiates a Japan bridging study to Support Surufatinib
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
MeMed BV is a first-of-its-kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
New Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline the transition from research to clinical environments
Clindamycin Phosphate Foam, 1% is the generic version of Evoclin Foam, 1%
The recipient is a 57-year-old woman who was suffering from severe biventricular heart failure and had undergone cardiac surgery several years ago
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting
The investment will be used to develop affordable Point of Care labs with 70+ tests. Mylab will start deploying systems with its lab partners from Nov 2021
The investment will be used to develop affordable Point of Care labs with 70+ tests. Mylab will start deploying systems with its lab partners from Nov 2021
RxDx is a chain of primary care driven multispecialty healthcare clinics with two main branches situated in Whitefield and Malleswaram in Bengaluru
It is the first-ever fully remote end-to-end Remote Patient Monitoring (RPM) service to include cardiac arrhythmia analysis in a single, intuitive platform
Subscribe To Our Newsletter & Stay Updated
